Plaque, Atherosclerotic Clinical Trial
Official title:
A Multi-Center, Randomized, Open-label, Parallel, Controlled Phase Ⅳ Clinical Trial to Evaluate the Effect of Inclisiran on Coronary Atherosclerotic Plaque in Patients With Acute Myocardial Infarction and Elevated Low-density Lipoprotein Cholesterol
This study is to evaluate the effect of Inclisiran on coronary atherosclerosis using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in patients with acute myocardial infarction and elevated low-density lipoprotein cholesterol (LDL-C).
This study will be a multi-center, randomized, parallel-group, open-label, phase 4 study. Participants will be approximately 318 Chinese adults diagnosed with new-onset STEMI/NSTEMI and elevated LDL-C (LDL-C > 1.8 mmol/L if on stable dose of statin (with or without ezetimibe) for ≥ 4 weeks; LDL-C > 2.6 mmol/L if not on stable dose of statin (with or without ezetimibe) for ≥ 4 weeks). Participants will be 1:1 randomized to investigational group (Inclisiran 284mg + 20mg atorvastatin) or control group (20mg atorvastatin) for 360 days. Participants and investigator will be unblinded to the identity of the treatment from the time of randomization. Independent Review Committee (IRC) staff performing the study assessments (IVUS and OCT analysis) will be blinded to the identity of the treatment from the time of randomization until final database lock. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03314818 -
Natural History of Carotid Plaque as Determined by 3D Ultrasound
|
N/A | |
Active, not recruiting |
NCT02374775 -
Exploring the MEchanism of Plaque Rupture in Acute Coronary Syndrome Using Coronary CT Angiography and computationaL Fluid Dynamic
|
N/A | |
Completed |
NCT01905566 -
Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation
|
Phase 4 | |
Not yet recruiting |
NCT05753085 -
Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment
|
N/A | |
Not yet recruiting |
NCT04524117 -
Prediction of Vulnerable Plaque Using Coronary CT Angiography and Computational Fluid Dynamic in Acute Coronary Syndrome
|
||
Recruiting |
NCT05123287 -
A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
|
||
Completed |
NCT02316886 -
Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque
|
Phase 4 | |
Terminated |
NCT02009930 -
Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service
|
||
Recruiting |
NCT04922541 -
Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
|
||
Not yet recruiting |
NCT06305559 -
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
|
Phase 3 | |
Recruiting |
NCT03016910 -
Coronary Artery Plaque Burden and Morphology in Type 2 Diabetes Mellitus.
|
N/A | |
Completed |
NCT03064126 -
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
|
Phase 3 | |
Recruiting |
NCT05550077 -
Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis
|
||
Completed |
NCT02212470 -
Drug Eluting Balloon Angioplasty Versus Nitinol Stent Implantation in the Superficial Femoral Artery
|
Phase 4 | |
Active, not recruiting |
NCT01899014 -
18F-choline PET-CT and MRI of Carotid Plaques
|
Phase 3 | |
Recruiting |
NCT04063709 -
Transcutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk
|
N/A | |
Enrolling by invitation |
NCT06025305 -
Identifying Vulnerable CoronAry PLaqUes With Artificial IntElligence-assisted CT Angiography
|
||
Completed |
NCT01559493 -
Fractional Flow Reserve (FFR) Versus Instant Wave-Free Ratio (iFR)
|
N/A | |
Active, not recruiting |
NCT04009421 -
Coronary Artery Plaque Burden in Stable Angina and Non-obstructive Coronary Artery Disease
|
||
Recruiting |
NCT02640313 -
Molecular Imaging of Plaque Vulnerability
|
Phase 3 |